mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects
To identify the most efficient methods of immunological protection against SARS-CoV-2, including the currently most widespread variants of concern (VOCs)—B.1.1.7, B.1.351 and P.1—a simultaneous side-by-side-comparison of available vaccination regimes is required. In this observational cohort study,...
| Автори: | , , , , , , , , , , , , , , |
|---|---|
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
MDPI AG
2021-08-01
|
| Серія: | Vaccines |
| Предмети: | |
| Онлайн доступ: | https://www.mdpi.com/2076-393X/9/8/918 |
| _version_ | 1829454437838487552 |
|---|---|
| author | Dorit Fabricius Carolin Ludwig Judith Scholz Immanuel Rode Chrysanthi Tsamadou Eva-Maria Jacobsen Martina Winkelmann Aline Grempels Ramin Lotfi Aleš Janda Sixten Körper Guido Adler Klaus-Michael Debatin Hubert Schrezenmeier Bernd Jahrsdörfer |
| author_facet | Dorit Fabricius Carolin Ludwig Judith Scholz Immanuel Rode Chrysanthi Tsamadou Eva-Maria Jacobsen Martina Winkelmann Aline Grempels Ramin Lotfi Aleš Janda Sixten Körper Guido Adler Klaus-Michael Debatin Hubert Schrezenmeier Bernd Jahrsdörfer |
| author_sort | Dorit Fabricius |
| collection | DOAJ |
| description | To identify the most efficient methods of immunological protection against SARS-CoV-2, including the currently most widespread variants of concern (VOCs)—B.1.1.7, B.1.351 and P.1—a simultaneous side-by-side-comparison of available vaccination regimes is required. In this observational cohort study, we compared immunological responses in 144 individuals vaccinated with the mRNA vaccines BNT162b2 or mRNA-1273 and the vector vaccine ChAdOx1-nCoV-19, either alone, in combination, or in the context of COVID-19-convalescence. Unvaccinated COVID-19-convalescent subjects served as a reference. We found that cellular and serological immune responses, including neutralizing capacity against VOCs, were significantly stronger with mRNA vaccines as compared with COVID-19-convalescent individuals or vaccinated individuals receiving the vector vaccine ChAdOx1-nCoV-19. Booster immunizations with mRNA vaccines triggered strong and broadly neutralizing antibody and IFN-γ responses in 100% of vaccinated individuals investigated. This effect was particularly strong in COVID-19-convalescent and ChAdOx1-nCoV-19-primed individuals, who were characterized by comparably moderate cellular and neutralizing antibody responses before mRNA vaccine booster. Heterologous vaccination regimes and convalescent booster regimes using mRNA vaccines may allow enhanced protection against SARS-CoV-2, including current VOCs. Furthermore, such regimes may facilitate rapid (re-)qualification of convalescent plasma donors with high titers of broadly neutralizing antibodies. |
| first_indexed | 2024-03-10T08:18:52Z |
| format | Article |
| id | doaj.art-b34f0c5ef6774f098e7f53ae0cb15acf |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T08:18:52Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-b34f0c5ef6774f098e7f53ae0cb15acf2023-11-22T10:08:00ZengMDPI AGVaccines2076-393X2021-08-019891810.3390/vaccines9080918mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed SubjectsDorit Fabricius0Carolin Ludwig1Judith Scholz2Immanuel Rode3Chrysanthi Tsamadou4Eva-Maria Jacobsen5Martina Winkelmann6Aline Grempels7Ramin Lotfi8Aleš Janda9Sixten Körper10Guido Adler11Klaus-Michael Debatin12Hubert Schrezenmeier13Bernd Jahrsdörfer14Division of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyDivision of Immune Cell Therapeutics, Institute of Clinical Transfusion Medicine and Immunogenetics, Helmholtzstrasse 10, 89081 Ulm, GermanyTo identify the most efficient methods of immunological protection against SARS-CoV-2, including the currently most widespread variants of concern (VOCs)—B.1.1.7, B.1.351 and P.1—a simultaneous side-by-side-comparison of available vaccination regimes is required. In this observational cohort study, we compared immunological responses in 144 individuals vaccinated with the mRNA vaccines BNT162b2 or mRNA-1273 and the vector vaccine ChAdOx1-nCoV-19, either alone, in combination, or in the context of COVID-19-convalescence. Unvaccinated COVID-19-convalescent subjects served as a reference. We found that cellular and serological immune responses, including neutralizing capacity against VOCs, were significantly stronger with mRNA vaccines as compared with COVID-19-convalescent individuals or vaccinated individuals receiving the vector vaccine ChAdOx1-nCoV-19. Booster immunizations with mRNA vaccines triggered strong and broadly neutralizing antibody and IFN-γ responses in 100% of vaccinated individuals investigated. This effect was particularly strong in COVID-19-convalescent and ChAdOx1-nCoV-19-primed individuals, who were characterized by comparably moderate cellular and neutralizing antibody responses before mRNA vaccine booster. Heterologous vaccination regimes and convalescent booster regimes using mRNA vaccines may allow enhanced protection against SARS-CoV-2, including current VOCs. Furthermore, such regimes may facilitate rapid (re-)qualification of convalescent plasma donors with high titers of broadly neutralizing antibodies.https://www.mdpi.com/2076-393X/9/8/918heterologous vaccination regimes using mRNA vaccines may allow enhanced protection against SARS-CoV-2, including current VOCsRNA vaccines may facilitate rapid (re-) qualification of convalescent plasma donors with high titers of broadly neutralizing antibodies |
| spellingShingle | Dorit Fabricius Carolin Ludwig Judith Scholz Immanuel Rode Chrysanthi Tsamadou Eva-Maria Jacobsen Martina Winkelmann Aline Grempels Ramin Lotfi Aleš Janda Sixten Körper Guido Adler Klaus-Michael Debatin Hubert Schrezenmeier Bernd Jahrsdörfer mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects Vaccines heterologous vaccination regimes using mRNA vaccines may allow enhanced protection against SARS-CoV-2, including current VOCs RNA vaccines may facilitate rapid (re-) qualification of convalescent plasma donors with high titers of broadly neutralizing antibodies |
| title | mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects |
| title_full | mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects |
| title_fullStr | mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects |
| title_full_unstemmed | mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects |
| title_short | mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects |
| title_sort | mrna vaccines enhance neutralizing immunity against sars cov 2 variants in convalescent and chadox1 primed subjects |
| topic | heterologous vaccination regimes using mRNA vaccines may allow enhanced protection against SARS-CoV-2, including current VOCs RNA vaccines may facilitate rapid (re-) qualification of convalescent plasma donors with high titers of broadly neutralizing antibodies |
| url | https://www.mdpi.com/2076-393X/9/8/918 |
| work_keys_str_mv | AT doritfabricius mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT carolinludwig mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT judithscholz mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT immanuelrode mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT chrysanthitsamadou mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT evamariajacobsen mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT martinawinkelmann mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT alinegrempels mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT raminlotfi mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT alesjanda mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT sixtenkorper mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT guidoadler mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT klausmichaeldebatin mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT hubertschrezenmeier mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects AT berndjahrsdorfer mrnavaccinesenhanceneutralizingimmunityagainstsarscov2variantsinconvalescentandchadox1primedsubjects |